Pulse Biosciences (PLSE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.28
- Estimate
- -$0.28
- Surprise
- +1.5%
- Revenue (period 2026-06-30)
- $434,000
- Score today
- 4.6/10
Revenue source: xbrl.
How the report landed
Pulse Biosciences (PLSE) reported adjusted EPS of -$0.28, in line with the -$0.28 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PLSE Sell at 4.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +1.5% surprise compares with a +3.1% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Target reached (-5.0% upside)
- Quality below floor (1.8 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $57.06
- Stop
- $53.07
Risk check: RSI 76 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
PLSE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $4.07B
- P/E (fwd)
- -48.8
- 52-week range
- $12.56–$58.90
- Off 52-week high
- 3.1%
- RSI (14)
- 76
- Volume vs avg
- 1.33×
- Score today
- 4.6/10